Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 30;8(1):115.
doi: 10.1186/s41687-024-00783-z.

Patient-reported outcome measures for lupus nephritis: content validity of LupusQoL and FACIT-Fatigue

Mona L Martin  1 , Jennifer N Hill  1 , Jennifer L Rogers  2 , Deven Chauhan  3 , Wen-Hung Chen #  4 , Kerry Gairy #  3
Affiliations

Patient-reported outcome measures for lupus nephritis: content validity of LupusQoL and FACIT-Fatigue

Mona L Martin et al. J Patient Rep Outcomes. .

Abstract
in English, German

Background: Lupus nephritis (LN), a severe organ manifestation of systemic lupus erythematosus (SLE), significantly impacts health-related quality of life (HRQoL). Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) and Lupus Quality of Life (LupusQoL) have been validated to measure HRQoL in SLE, but not specifically in LN. Patient-reported symptoms of LN are not well-reported. We assessed the content validity and relevance of these measures in evaluating patients with LN and their LN-related experiences.

Methods: This qualitative, interview-based study enrolled patients with LN from three US sites from a larger, retrospective survey study. The interview comprised an open-ended concept elicitation part and a more structured cognitive part. Concept elicitation was used to identify relevant themes describing the patients' experiences. Patients were asked to describe their LN-related symptoms, the severity and impact of those symptoms and their satisfaction with treatment. A cognitive interview approach evaluated the appropriate understanding of the items, instructions, and response options and asked patients about their understanding of the FACIT-Fatigue or LupusQoL measures, their relevance to the condition, and any aspects of confusion or need for better clarity of the questionnaires. All interviews were recorded and transcribed. The concept elicitation data were coded, while the cognitive interview data were tabulated to present the participants' responses next to the interview questions to support the evaluation of their understanding of the questionnaire items.

Results: Overall, 10 patients participated in FACIT-Fatigue and another 10 in LupusQoL interviews; 18 patients were female, 10 were Black (self-reported) and 17 were receiving maintenance treatment for LN with stable disease activity. When patients recalled their symptoms, 670 expressions of varying symptoms were reported. All patients described pain, discomfort, and energy-related symptoms. Urinary frequency and non-joint swelling were most frequently attributed to LN rather than SLE. Patients felt the questions asked in the FACIT-Fatigue and LupusQoL surveys were relevant to their LN experience.

Conclusions: The symptoms reported by patients with LN were consistent with symptoms reported by the overall SLE population. However, patients indicated that some symptoms of LN were more profound than symptoms of SLE alone, affecting a broad range of areas of daily life activity and resulting in a higher burden on their HRQoL. FACIT-Fatigue and LupusQoL demonstrated content relevance as meaningful tools for patients with LN. However, further quantitative data collection is needed to ensure that these patient-reported outcome tools demonstrate good measurement properties in an LN population.

Lupus nephritis (LN) is a kidney involvement in many patients with systemic lupus erythematosus (SLE). SLE patients with LN may have clinical symptoms that include tiredness and changes regarding urine, in addition to those related to SLE itself, like rashes, joint pain and swelling. The symptoms can be mild, moderate or severe and can affect quality of life. It is important to learn the effects of these symptoms directly from the patients; understanding patients’ experiences will help their medical team monitor the disease and treatment more effectively. Questionnaires are often used to evaluate symptoms and the impact of these symptoms on patients’ lives. Two questionnaires, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) and Lupus Quality of Life (LupusQoL), were used to assess symptoms and the effect of LN on the patients’ lives. First, patients were asked to describe their signs and symptoms and how these affect their lives. Then, patients were asked about their understanding of the individual questions. We found that all patients reported symptoms of tiredness and joint pain. Increased urinary frequency, swelling in non-joints, and frequent infections were reported more often by patients with LN than those with SLE alone. Patients said that their manifestations greatly affect their everyday lives. There was a good understanding of the questionnaires, and patients felt the questions were relevant to them. This is an important step to validate FACIT-Fatigue and LupusQoL. This study shows that the FACIT-Fatigue and the LupusQoL can be used when assessing people with LN.

Keywords: Content validity; FACIT-Fatigue; Lupus nephritis; LupusQoL; Patient-reported outcomes; Quality of life.

PubMed Disclaimer

Conflict of interest statement

MLM is an employee of Evidera, a company contracted by GSK to carry out this study. JNH was an employee of Evidera, a company contracted by GSK to carry out this study, at the time of the study. DC is an employee of GSK and holds financial equities in GSK. KG and W-HC were employees of GSK at the time of the study and hold financial equities in GSK. JLR has nothing to disclose pertaining to the work.

Similar articles

See all similar articles

References

    1. Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT (2021) Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 80:14–25. 10.1136/annrheumdis-2020-218272 - PubMed
    1. Herrada AA, Escobedo N, Iruretagoyena M, Valenzuela RA, Burgos PI, Cuitino L, Llanos C (2019) Innate immune cells’ contribution to systemic lupus erythematosus. Front Immunol 10:772. 10.3389/fimmu.2019.00772 - PMC - PubMed
    1. Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin P, Gladman DD, Sanchez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarcón GS, Fessler BJ, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta MA, van Vollenhoven RF, Zoma AA, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V (2016) The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 55:252–262. 10.1093/rheumatology/kev311 - PMC - PubMed
    1. Fukuhara S, Lopes AA, Bragg-Gresham JL, Kurokawa K, Mapes DL, Akizawa T, Bommer J, Canaud BJ, Port FK, Held PJ, Worldwide Dialysis O, Practice Patterns S (2003) Health-related quality of life among dialysis patients on three continents: the Dialysis outcomes and practice patterns study. Kidney Int 64:1903–1910. 10.1046/j.1523-1755.2003.00289.x - PubMed
    1. Tektonidou MG, Dasgupta A, Ward MM (2016) Risk of end-stage renal disease in patients with Lupus Nephritis, 1971–2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol 68:1432–1441. 10.1002/art.39594 - PMC - PubMed

Grants and funding

LinkOut - more resources